Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Small Cell Lung Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Lung Cancer (4108
)
Non Small Cell Lung Cancer (3691
)
Lung Cancer (4108
)
Non Small Cell Lung Cancer (3691
)
›
Associations
(155)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
topotecan
Sensitive: A1 - Approval
topotecan
Sensitive
:
A1
topotecan
Sensitive: A1 - Approval
topotecan
Sensitive
:
A1
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
lurbinectedin
Sensitive: A1 - Approval
lurbinectedin
Sensitive
:
A1
lurbinectedin
Sensitive: A1 - Approval
lurbinectedin
Sensitive
:
A1
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
serplulimab
Sensitive: A1 - Approval
serplulimab
Sensitive
:
A1
serplulimab
Sensitive: A1 - Approval
serplulimab
Sensitive
:
A1
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
CAV
Sensitive: A2 - Guideline
CAV
Sensitive
:
A2
CAV
Sensitive: A2 - Guideline
CAV
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
temozolomide
Sensitive: A2 - Guideline
temozolomide
Sensitive
:
A2
temozolomide
Sensitive: A2 - Guideline
temozolomide
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
vinorelbine tartrate
Sensitive: A2 - Guideline
vinorelbine tartrate
Sensitive
:
A2
vinorelbine tartrate
Sensitive: A2 - Guideline
vinorelbine tartrate
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
irinotecan
Sensitive: A2 - Guideline
irinotecan
Sensitive
:
A2
irinotecan
Sensitive: A2 - Guideline
irinotecan
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
bevacizumab
Resistant: A2 - Guideline
bevacizumab
Resistant
:
A2
bevacizumab
Resistant: A2 - Guideline
bevacizumab
Resistant
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
carboplatin
Sensitive: A2 - Guideline
carboplatin
Sensitive
:
A2
carboplatin
Sensitive: A2 - Guideline
carboplatin
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
carboplatin + etoposide IV
Sensitive: A2 - Guideline
carboplatin + etoposide IV
Sensitive
:
A2
carboplatin + etoposide IV
Sensitive: A2 - Guideline
carboplatin + etoposide IV
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
cisplatin + etoposide IV
Sensitive: A2 - Guideline
cisplatin + etoposide IV
Sensitive
:
A2
cisplatin + etoposide IV
Sensitive: A2 - Guideline
cisplatin + etoposide IV
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
carboplatin + gemcitabine
Sensitive: A2 - Guideline
carboplatin + gemcitabine
Sensitive
:
A2
carboplatin + gemcitabine
Sensitive: A2 - Guideline
carboplatin + gemcitabine
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
cisplatin + topotecan
Sensitive: A2 - Guideline
cisplatin + topotecan
Sensitive
:
A2
cisplatin + topotecan
Sensitive: A2 - Guideline
cisplatin + topotecan
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
cisplatin + irinotecan
Sensitive: A2 - Guideline
cisplatin + irinotecan
Sensitive
:
A2
cisplatin + irinotecan
Sensitive: A2 - Guideline
cisplatin + irinotecan
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
trilaciclib
Sensitive: B - Late Trials
trilaciclib
Sensitive
:
B
trilaciclib
Sensitive: B - Late Trials
trilaciclib
Sensitive
:
B
PD-L1 expression
Small Cell Lung Cancer
PD-L1 expression
Small Cell Lung Cancer
atezolizumab
Sensitive: B - Late Trials
atezolizumab
Sensitive
:
B
atezolizumab
Sensitive: B - Late Trials
atezolizumab
Sensitive
:
B
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
CS 2164
Sensitive: B - Late Trials
CS 2164
Sensitive
:
B
CS 2164
Sensitive: B - Late Trials
CS 2164
Sensitive
:
B
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
nanoliposomal irinotecan
Sensitive: B - Late Trials
nanoliposomal irinotecan
Sensitive
:
B
nanoliposomal irinotecan
Sensitive: B - Late Trials
nanoliposomal irinotecan
Sensitive
:
B
DLL3 overexpression
Small Cell Lung Cancer
DLL3 overexpression
Small Cell Lung Cancer
rovalpituzumab tesirine
Sensitive: B - Late Trials
rovalpituzumab tesirine
Sensitive
:
B
rovalpituzumab tesirine
Sensitive: B - Late Trials
rovalpituzumab tesirine
Sensitive
:
B
TMB-H
Small Cell Lung Cancer
TMB-H
Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: B - Late Trials
nivolumab + ipilimumab
Sensitive
:
B
nivolumab + ipilimumab
Sensitive: B - Late Trials
nivolumab + ipilimumab
Sensitive
:
B
TMB-H
Small Cell Lung Cancer
TMB-H
Small Cell Lung Cancer
nivolumab
Sensitive: B - Late Trials
nivolumab
Sensitive
:
B
nivolumab
Sensitive: B - Late Trials
nivolumab
Sensitive
:
B
HLA-DQB1*03:01
Small Cell Lung Cancer
HLA-DQB1*03:01
Small Cell Lung Cancer
durvalumab + tremelimumab
Sensitive: B - Late Trials
durvalumab + tremelimumab
Sensitive
:
B
durvalumab + tremelimumab
Sensitive: B - Late Trials
durvalumab + tremelimumab
Sensitive
:
B
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login